DE68927230T2 - Vaskulares magnetisches bildformungsverfahren - Google Patents

Vaskulares magnetisches bildformungsverfahren

Info

Publication number
DE68927230T2
DE68927230T2 DE68927230T DE68927230T DE68927230T2 DE 68927230 T2 DE68927230 T2 DE 68927230T2 DE 68927230 T DE68927230 T DE 68927230T DE 68927230 T DE68927230 T DE 68927230T DE 68927230 T2 DE68927230 T2 DE 68927230T2
Authority
DE
Germany
Prior art keywords
aggregates
preparation
imaging contrast
angstroms
comprised
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE68927230T
Other languages
English (en)
Other versions
DE68927230D1 (de
Inventor
Jerome Lewis
Edward Menz
Francis Kenny
Ernest Groman
Lee Josephson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Amag Pharmaceuticals Inc
Original Assignee
Advanced Magnetics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22876212&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DE68927230(T2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Advanced Magnetics Inc filed Critical Advanced Magnetics Inc
Application granted granted Critical
Publication of DE68927230D1 publication Critical patent/DE68927230D1/de
Publication of DE68927230T2 publication Critical patent/DE68927230T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01R—MEASURING ELECTRIC VARIABLES; MEASURING MAGNETIC VARIABLES
    • G01R33/00—Arrangements or instruments for measuring magnetic variables
    • G01R33/20—Arrangements or instruments for measuring magnetic variables involving magnetic resonance
    • G01R33/44—Arrangements or instruments for measuring magnetic variables involving magnetic resonance using nuclear magnetic resonance [NMR]
    • G01R33/48—NMR imaging systems
    • G01R33/54—Signal processing systems, e.g. using pulse sequences ; Generation or control of pulse sequences; Operator console
    • G01R33/56—Image enhancement or correction, e.g. subtraction or averaging techniques, e.g. improvement of signal-to-noise ratio and resolution
    • G01R33/5601—Image enhancement or correction, e.g. subtraction or averaging techniques, e.g. improvement of signal-to-noise ratio and resolution involving use of a contrast agent for contrast manipulation, e.g. a paramagnetic, super-paramagnetic, ferromagnetic or hyperpolarised contrast agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/18—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/18—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes
    • A61K49/1818—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles
    • A61K49/1821—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles
    • A61K49/1824—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles
    • A61K49/1827—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles having a (super)(para)magnetic core, being a solid MRI-active material, e.g. magnetite, or composed of a plurality of MRI-active, organic agents, e.g. Gd-chelates, or nuclei, e.g. Eu3+, encapsulated or entrapped in the core of the coated or functionalised nanoparticle
    • A61K49/1851—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles having a (super)(para)magnetic core, being a solid MRI-active material, e.g. magnetite, or composed of a plurality of MRI-active, organic agents, e.g. Gd-chelates, or nuclei, e.g. Eu3+, encapsulated or entrapped in the core of the coated or functionalised nanoparticle having a (super)(para)magnetic core coated or functionalised with an organic macromolecular compound, i.e. oligomeric, polymeric, dendrimeric organic molecule
    • A61K49/1863—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles having a (super)(para)magnetic core, being a solid MRI-active material, e.g. magnetite, or composed of a plurality of MRI-active, organic agents, e.g. Gd-chelates, or nuclei, e.g. Eu3+, encapsulated or entrapped in the core of the coated or functionalised nanoparticle having a (super)(para)magnetic core coated or functionalised with an organic macromolecular compound, i.e. oligomeric, polymeric, dendrimeric organic molecule the organic macromolecular compound being a polysaccharide or derivative thereof, e.g. chitosan, chitin, cellulose, pectin, starch
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/18—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes
    • A61K49/1818—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles
    • A61K49/1887—Agglomerates, clusters, i.e. more than one (super)(para)magnetic microparticle or nanoparticle are aggregated or entrapped in the same maxtrix
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G18/00—Polymeric products of isocyanates or isothiocyanates
    • C08G18/06—Polymeric products of isocyanates or isothiocyanates with compounds having active hydrogen
    • C08G18/08—Processes
    • C08G18/16—Catalysts
    • C08G18/18—Catalysts containing secondary or tertiary amines or salts thereof
    • C08G18/1808—Catalysts containing secondary or tertiary amines or salts thereof having alkylene polyamine groups
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G18/00—Polymeric products of isocyanates or isothiocyanates
    • C08G18/06—Polymeric products of isocyanates or isothiocyanates with compounds having active hydrogen
    • C08G18/08—Processes
    • C08G18/16—Catalysts
    • C08G18/18—Catalysts containing secondary or tertiary amines or salts thereof
    • C08G18/1816—Catalysts containing secondary or tertiary amines or salts thereof having carbocyclic groups
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G18/00—Polymeric products of isocyanates or isothiocyanates
    • C08G18/06—Polymeric products of isocyanates or isothiocyanates with compounds having active hydrogen
    • C08G18/08—Processes
    • C08G18/16—Catalysts
    • C08G18/18—Catalysts containing secondary or tertiary amines or salts thereof
    • C08G18/1825—Catalysts containing secondary or tertiary amines or salts thereof having hydroxy or primary amino groups
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G18/00—Polymeric products of isocyanates or isothiocyanates
    • C08G18/06—Polymeric products of isocyanates or isothiocyanates with compounds having active hydrogen
    • C08G18/08—Processes
    • C08G18/16—Catalysts
    • C08G18/18—Catalysts containing secondary or tertiary amines or salts thereof
    • C08G18/20—Heterocyclic amines; Salts thereof
    • C08G18/2009—Heterocyclic amines; Salts thereof containing one heterocyclic ring
    • C08G18/2036—Heterocyclic amines; Salts thereof containing one heterocyclic ring having at least three nitrogen atoms in the ring
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G18/00—Polymeric products of isocyanates or isothiocyanates
    • C08G18/06—Polymeric products of isocyanates or isothiocyanates with compounds having active hydrogen
    • C08G18/08—Processes
    • C08G18/16—Catalysts
    • C08G18/22—Catalysts containing metal compounds
    • C08G18/24—Catalysts containing metal compounds of tin
    • C08G18/244—Catalysts containing metal compounds of tin tin salts of carboxylic acids
    • C08G18/246—Catalysts containing metal compounds of tin tin salts of carboxylic acids containing also tin-carbon bonds
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G18/00—Polymeric products of isocyanates or isothiocyanates
    • C08G18/06—Polymeric products of isocyanates or isothiocyanates with compounds having active hydrogen
    • C08G18/08—Processes
    • C08G18/16—Catalysts
    • C08G18/22—Catalysts containing metal compounds
    • C08G18/26—Catalysts containing metal compounds of lead
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08J—WORKING-UP; GENERAL PROCESSES OF COMPOUNDING; AFTER-TREATMENT NOT COVERED BY SUBCLASSES C08B, C08C, C08F, C08G or C08H
    • C08J9/00—Working-up of macromolecular substances to porous or cellular articles or materials; After-treatment thereof
    • C08J9/04—Working-up of macromolecular substances to porous or cellular articles or materials; After-treatment thereof using blowing gases generated by a previously added blowing agent
    • C08J9/12—Working-up of macromolecular substances to porous or cellular articles or materials; After-treatment thereof using blowing gases generated by a previously added blowing agent by a physical blowing agent
    • C08J9/14—Working-up of macromolecular substances to porous or cellular articles or materials; After-treatment thereof using blowing gases generated by a previously added blowing agent by a physical blowing agent organic
    • C08J9/143—Halogen containing compounds
    • C08J9/144—Halogen containing compounds containing carbon, halogen and hydrogen only
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G2101/00—Manufacture of cellular products
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08J—WORKING-UP; GENERAL PROCESSES OF COMPOUNDING; AFTER-TREATMENT NOT COVERED BY SUBCLASSES C08B, C08C, C08F, C08G or C08H
    • C08J2375/00—Characterised by the use of polyureas or polyurethanes; Derivatives of such polymers
    • C08J2375/04—Polyurethanes
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T436/00—Chemistry: analytical and immunological testing
    • Y10T436/24—Nuclear magnetic resonance, electron spin resonance or other spin effects or mass spectrometry

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Nanotechnology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Polymers & Plastics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Radiology & Medical Imaging (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Physics & Mathematics (AREA)
  • Molecular Biology (AREA)
  • Materials Engineering (AREA)
  • Signal Processing (AREA)
  • Immunology (AREA)
  • High Energy & Nuclear Physics (AREA)
  • Condensed Matter Physics & Semiconductors (AREA)
  • General Physics & Mathematics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Medical Informatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Magnetic Resonance Imaging Apparatus (AREA)
DE68927230T 1988-08-16 1989-08-16 Vaskulares magnetisches bildformungsverfahren Expired - Lifetime DE68927230T2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US07/233,177 US5055288A (en) 1987-06-26 1988-08-16 Vascular magnetic imaging method and agent comprising biodegradeable superparamagnetic metal oxides
PCT/US1989/003517 WO1990001899A1 (en) 1988-08-16 1989-08-16 Vascular magnetic imaging method and agent

Publications (2)

Publication Number Publication Date
DE68927230D1 DE68927230D1 (de) 1996-10-24
DE68927230T2 true DE68927230T2 (de) 1997-02-06

Family

ID=22876212

Family Applications (1)

Application Number Title Priority Date Filing Date
DE68927230T Expired - Lifetime DE68927230T2 (de) 1988-08-16 1989-08-16 Vaskulares magnetisches bildformungsverfahren

Country Status (5)

Country Link
US (1) US5055288A (de)
EP (1) EP0441797B1 (de)
AT (1) ATE142891T1 (de)
DE (1) DE68927230T2 (de)
WO (1) WO1990001899A1 (de)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT81498B (pt) * 1984-11-23 1987-12-30 Schering Ag Processo para a preparacao de composicoes para diagnostico contendo particulas magneticas
US5597531A (en) † 1985-10-04 1997-01-28 Immunivest Corporation Resuspendable coated magnetic particles and stable magnetic particle suspensions
US5262176A (en) * 1986-07-03 1993-11-16 Advanced Magnetics, Inc. Synthesis of polysaccharide covered superparamagnetic oxide colloids
US5102652A (en) * 1986-07-03 1992-04-07 Advanced Magnetics Inc. Low molecular weight carbohydrates as additives to stabilize metal oxide compositions
US5213788A (en) * 1988-09-29 1993-05-25 Ranney David F Physically and chemically stabilized polyatomic clusters for magnetic resonance image and spectral enhancement
US5114703A (en) * 1989-05-30 1992-05-19 Alliance Pharmaceutical Corp. Percutaneous lymphography using particulate fluorocarbon emulsions
US5377681A (en) * 1989-11-13 1995-01-03 University Of Florida Method of diagnosing impaired blood flow
IL98744A0 (en) * 1990-07-06 1992-07-15 Gen Hospital Corp Method of studying biological tissue using monocrystalline particles
DE4117782C2 (de) * 1991-05-28 1997-07-17 Diagnostikforschung Inst Nanokristalline magnetische Eisenoxid-Partikel, Verfahren zu ihrer Herstellung sowie diagnostische und/oder therapeutische Mittel
DE69207589T2 (de) 1992-06-01 1996-05-23 Basf Ag Anwendung von Dispersionen von magneto-ionischen Partikeln in MRI-Kontrast-Mitteln
US5323780A (en) * 1992-08-07 1994-06-28 University Of Florida Research Foundation, Inc. Artifact-free imaging contrast agent
DE4239442C2 (de) * 1992-11-24 2001-09-13 Sebo Gmbh Verwendung eines mit polynuklearen Metalloxidhydroxiden modifizierten Adsorptionsmaterials zur selektiven Elimination von anorganischem Phosphat aus proteinhaltigen Flüssigkeiten
US5349957A (en) * 1992-12-02 1994-09-27 Sterling Winthrop Inc. Preparation and magnetic properties of very small magnetite-dextran particles
US5298262A (en) * 1992-12-04 1994-03-29 Sterling Winthrop Inc. Use of ionic cloud point modifiers to prevent particle aggregation during sterilization
US5551429A (en) * 1993-02-12 1996-09-03 Fitzpatrick; J. Michael Method for relating the data of an image space to physical space
JPH08508721A (ja) * 1993-03-17 1996-09-17 シリカゲル ゲス．エム．ビー．エイチ 超常磁性粒子、その製法及びその用途
US5590654A (en) 1993-06-07 1997-01-07 Prince; Martin R. Method and apparatus for magnetic resonance imaging of arteries using a magnetic resonance contrast agent
US5579767A (en) 1993-06-07 1996-12-03 Prince; Martin R. Method for imaging abdominal aorta and aortic aneurysms
US5417213A (en) * 1993-06-07 1995-05-23 Prince; Martin R. Magnetic resonance arteriography with dynamic intravenous contrast agents
GB9407512D0 (en) * 1994-04-15 1994-06-08 Ici Plc Catalysts
US6122540A (en) * 1994-06-08 2000-09-19 The Regents Of The University Of California Noninvasive measurement of renal hemodynamic functions using magnetic resonance imaging
DK0783325T3 (da) * 1994-09-27 2000-05-01 Nycomed Imaging As Kontrastmiddel
DE19509694A1 (de) * 1995-03-08 1996-09-19 Schering Ag Verwendung von Magnetiten zur Bestimmung der Perfusion von menschlichem Gewebe mittels MR-Diagnostik
US6333971B2 (en) 1995-06-07 2001-12-25 George S. Allen Fiducial marker
JP4280304B2 (ja) 1996-01-10 2009-06-17 ジーイー・ヘルスケア・アクスイェ・セルスカプ 造影剤
GB9600427D0 (en) * 1996-01-10 1996-03-13 Nycomed Imaging As Contrast media
DE19612001A1 (de) * 1996-03-18 1997-09-25 Silica Gel Gmbh Adsorptions Te Superparamagnetische Teilchen mit vergrößerter R¶1¶-Relaxivität, Verfahren zur Herstellung und deren Verwendung
NZ333962A (en) 1996-08-05 2000-07-28 Schering Ag Process and device for the production of contrast media for magnetic resonance tomography
US5924987A (en) 1997-10-06 1999-07-20 Meaney; James F. M. Method and apparatus for magnetic resonance arteriography using contrast agents
US6093382A (en) 1998-05-16 2000-07-25 Bracco Research Usa Inc. Metal complexes derivatized with folate for use in diagnostic and therapeutic applications
US7871597B2 (en) 1999-04-09 2011-01-18 Amag Pharmaceuticals, Inc. Polyol and polyether iron oxide complexes as pharmacological and/or MRI contrast agents
DE60043188D1 (de) 1999-04-09 2009-12-03 Amag Pharmaceuticals Inc Hitzebeständige umhüllte kolloidale eisenoxide
GB9921579D0 (de) * 1999-09-13 1999-11-17 Nycomed Imaging As
US7082326B2 (en) 2000-03-31 2006-07-25 Amersham Health As Method of magnetic resonance imaging
US7169618B2 (en) 2000-06-28 2007-01-30 Skold Technology Magnetic particles and methods of producing coated magnetic particles
US20040225213A1 (en) 2002-01-22 2004-11-11 Xingwu Wang Magnetic resonance imaging coated assembly
DE10222481A1 (de) * 2002-05-22 2003-12-04 Eucro Europe Contract Res Gmbh Kontrastmittel für die Verwendung in bildgebenden Verfahren
JP2007511503A (ja) * 2003-11-17 2007-05-10 コーニンクレッカ フィリップス エレクトロニクス エヌ ヴィ 医療画像化技術用の造影剤及びその使用
US7670676B2 (en) * 2005-06-15 2010-03-02 Toda Kogyo Corporation Pharmaceutical raw material
ES2526171T3 (es) * 2006-12-14 2015-01-07 Novartis Ag Adsorbente de fosfato a base de hierro (III)-carbohidratos
CN101547706B (zh) * 2007-04-12 2013-07-10 延世大学校产学协力团 包含含锌磁性金属氧化物纳米颗粒的磁共振成像造影剂
US20100136517A1 (en) * 2007-05-07 2010-06-03 Massachusetts Institute Of Technology Matrix stabilization of aggregation-based assays
WO2009036441A2 (en) * 2007-09-14 2009-03-19 Northwestern University Contrast agents
US9125942B2 (en) * 2010-01-19 2015-09-08 Northwestern University Paramagnetic metal-nanodiamond conjugates
EP3302338B1 (de) 2015-06-04 2020-09-30 Endomagnetics Ltd. Markermaterialien und -formen zur lokalisierung magnetischer marker
US10788373B2 (en) 2018-05-29 2020-09-29 University Of Central Florida Research Foundation, Inc. Imaging device with loop bolometer array and related methods
WO2021178315A1 (en) * 2020-03-02 2021-09-10 Vanderbilt University Bioresorbable rf coils for post-surgical monitoring by mri

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE571966A (de) *
CA625770A (en) * 1961-08-15 R. K. Laros Company Iron-dextran composition
DE1196629B (de) * 1961-11-30 1965-07-15 Hausmann Ag Labor Verfahren zur Herstellung von nichtionischen, therapeutisch verwertbaren Ferrihydroxyd-Dextran-Komplexen
GB1200902A (en) * 1967-05-13 1970-08-05 Fisons Pharmaceuticals Ltd Iron-dextran complexes
DE1954960A1 (de) * 1968-11-01 1970-05-14 Christensen Dr Med Henry Marin Verfahren zur Herstellung von Eisen-Dextran-Praeparaten
US3697502A (en) * 1969-11-03 1972-10-10 Christensen Henry M Method of making iron dextran-preparations
US3980076A (en) * 1974-10-02 1976-09-14 The Board Of Trustees Of Leland Stanford Junior University Method for measuring externally of the human body magnetic susceptibility changes
JPS5913521B2 (ja) * 1975-06-19 1984-03-30 メイトウサンギヨウ カブシキガイシヤ 磁性酸化鉄・デキストラン複合体の製造法
DE3026868C2 (de) * 1980-07-16 1986-03-13 Laboratorien Hausmann AG, St. Gallen Verfahren zur Herstellung von Eisen(III)hydroxid-Dextran-Komplexen und sie enthaltende pharmazeutische sterile wäßrige Lösung
US4647447A (en) * 1981-07-24 1987-03-03 Schering Aktiengesellschaft Diagnostic media
US4452773A (en) * 1982-04-05 1984-06-05 Canadian Patents And Development Limited Magnetic iron-dextran microspheres
NO155316C (no) * 1982-04-23 1987-03-11 Sintef Fremgangsmaate for fremstilling av magnetiske polymerpartikler.
US4731239A (en) * 1983-01-10 1988-03-15 Gordon Robert T Method for enhancing NMR imaging; and diagnostic use
US4735796A (en) * 1983-12-08 1988-04-05 Gordon Robert T Ferromagnetic, diamagnetic or paramagnetic particles useful in the diagnosis and treatment of disease
US4695392A (en) * 1983-05-12 1987-09-22 Advanced Magnetics Inc. Magnetic particles for use in separations
SE463651B (sv) * 1983-12-21 1991-01-07 Nycomed As Diagnostikum och kontrastmedel
GB8408127D0 (en) * 1984-03-29 1984-05-10 Nyegaard & Co As Contrast agents
CA1268208A (en) * 1984-08-10 1990-04-24 Truman Brown Magnetic micro-particles as contrast agents in nuclear magnetic resonance imaging
PT81498B (pt) * 1984-11-23 1987-12-30 Schering Ag Processo para a preparacao de composicoes para diagnostico contendo particulas magneticas
DE3443251C2 (de) * 1984-11-23 1998-03-12 Schering Ag Eisenoxid-Komplexe für die NMR-Diagnostik, diese Verbindungen enthaltende diagnostische Mittel, ihre Verwendung und Verfahren zu deren Herstellung
US4849210A (en) * 1985-05-08 1989-07-18 Molecular Biosystems, Inc. Magnetic resonance imaging of liver and spleen with superparamagnetic contrast agents
US4675173A (en) * 1985-05-08 1987-06-23 Molecular Biosystems, Inc. Method of magnetic resonance imaging of the liver and spleen
DE3688613T2 (de) * 1985-11-18 1994-01-13 Access Pharma Inc Polychelierende stoffe für abbildung- und spektralerhöhung (und spektrale verschiebung).
US4770183A (en) 1986-07-03 1988-09-13 Advanced Magnetics Incorporated Biologically degradable superparamagnetic particles for use as nuclear magnetic resonance imaging agents
US4827945A (en) * 1986-07-03 1989-05-09 Advanced Magnetics, Incorporated Biologically degradable superparamagnetic materials for use in clinical applications
DE68926708T2 (de) * 1988-08-04 1996-10-31 Advanced Magnetics Inc Von einem rezeptor induziertes kontrastmittel für den endocytose-typ mri

Also Published As

Publication number Publication date
EP0441797B1 (de) 1996-09-18
EP0441797A4 (en) 1992-01-15
ATE142891T1 (de) 1996-10-15
EP0441797A1 (de) 1991-08-21
US5055288A (en) 1991-10-08
DE68927230D1 (de) 1996-10-24
WO1990001899A1 (en) 1990-03-08

Similar Documents

Publication Publication Date Title
DE68927230T2 (de) Vaskulares magnetisches bildformungsverfahren
US5315997A (en) Method of magnetic resonance imaging using diamagnetic contrast
Weissleder et al. Ultrasmall superparamagnetic iron oxide: characterization of a new class of contrast agents for MR imaging.
EP0708927B1 (de) Verfahren und zusammensetzungen zur erhöhung des bild-kontrastes
NO934425L (no) Preparater for nanopartikkelformige röntgenkontrastmidler
ATE99544T1 (de) Liposomale radiologische kontrastmittel.
EP0662005A1 (de) Mikropartikelpräparationen aus biologisch abbaubaren mischpolymeren
DE10199064I2 (de) Oxidierte Zusammensetzung, enthaltend ein wasserlösliches Carboxypolysaccharid und magnetisches Eisenoxid.
US5314681A (en) Composition of positive and negative contrast agents for electron spin resonance enhanced magnetic resonance imaging
EP0867729A1 (de) Magnetredonanzbildgebungstechnik mit Overhauserverstärkung (OMRI oder REDRI oder ESREMPI)
AU3944893A (en) Methods and compositions for magnetic resonance imaging
AU2320392A (en) Hydroxamate and hydrazide derivatives of polyamines and their medical use as chelating agents
US5855868A (en) Method of T1 -weighted resonance imaging of RES organs
US20030120151A1 (en) Magnetic resonance imaging methods and compositions
JP2911674B2 (ja) 消化管造影用組成物
EP1181570B1 (de) Verfahren zur bilderzeugung durch magnetische resonanz
GB2311138A (en) ESR-enhanced MRI using magnetic particles as contrast agents
EP0514493B1 (de) FILTERSTERILISATION ZUR HERSTELLUNG VON KOLLOIDALEN SUPERPARAMAGNETISCHEN MR-KONTRASTMITTELN und ihre Verwendung
DE19626530A1 (de) MR-Kontrastmittelzubereitungen
WO1993003671A1 (en) Method of mri imaging using diamagnetic contrast agents
JP2004508123A (ja) 粒子状造影剤を使用して核スピントモグラフィーにより血栓を画像表示及び診断する方法
Davis et al. Optimization of a negative oral contrast agent for magnetic resonance imaging
JPH04224523A (ja) Ｍｒｉ用造影剤
JPH05194277A (ja) Ｍｒｉ用造影剤
EP0599839A4 (en) Method of mri imaging using diamagnetic contrast agents.

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8327 Change in the person/name/address of the patent owner

Owner name: AMAG PHARMACEUTICALS,INC.(N.D.GES.D.STAATES DE, US